Welcome to the international HTA database

Showing [23378 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Inclisiran (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Incidence of errors in intensive care: effects of increased awareness and of improved communication by the introduction of explicit daily goals]
2006	Basque Office for Health Technology Assessment (OSTEBA)	[Incidence of diabetic retinopathy based on a screening programme using a non-mydriatic retinal camera on diabetic patients in the Autonomous Community of the Basque Country]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism - Addendum to commission H22-04]
2009	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[In vitro fertilization: comparative profile of European and Oceania countries]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Improving the efficiency and quality of follow-up after curative treatment for breast cancer]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Improving the early diagnosis of myocardial infarction in primary care: the added value of a rapid assay to detect heart-type FABP, a novel marker of cardiac injury]
2009	Basque Office for Health Technology Assessment (OSTEBA)	[Improving the care of elderly patients with chronic pathologies]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Improving lifestyle adherence in patients with high risk for cardiovascular diseases in general practice. Costs and effects of patient involvement in cardiovascular risk management]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementing a routine outcome monitoring system to study the effectiveness of long-term psychoanalytic treatment and therapeutic decision making in four cohorts of personality disordered and/ or recurrent or chronic depressive patients]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of the WIP guideline 'Prevention of infections due to urethral bladder catheterization']
2010	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of structural feedback by means of perinatal audit to caregivers in cases of perinatal mortality in the northern part of the Netherlands (IMPACT)]
2010	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of selective karyotyping in couples with recurrent miscarriage]
2012	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of screening and treatment of high-risk fracture patients by an osteoporosis nurse-practitioner]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Implementation of quality indicators to assess the high risk of colorectal cancer clinic]
2012	The Swedish Council on Health Technology Assessment (SBU)	[Implementation of psychiatric guidelines and evidence-based knowledge in the primary care sector]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of outpatient schema focused therapy for borderline personality disorder in three settings: general community mental health centers, forensic centers and addiction treatment centers]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of intensive insulin therapy (IIT) in critically ill patients, targeting at normoglycemia while preventing hypoglycemia]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implementation of guidelines - obstructive and beneficial factors]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of evidence-based guidelines for appropriate use of ultrasonography in diagnostic breast imaging: the MAMMOED-2 study]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of an evidence based smoking cessation strategy (SMOCC) for patients with COPD in primary care]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[IMPlementation of a prediction rule in Anesthesia practice to improve Cost-effectiveness of Treatment of postoperative nausea and vomiting: the IMPACT trial]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of a new cost-effective treatment (HIT) for patients with therapy refractory auditory hallucinations]
2012	The Netherlands Organisation for Health Research and Development (ZonMw)	[Implementation of a multiple intervention aimed at optimising prescription of antibiotics for respiratory tract infections, embedded within the new practice accreditation of the Dutch College of General Practitioners; a randomized controlled trial]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Implementation and development of a treatment programme for peritoneal carcinomatosis in Catalonia. Indications and clinical results using Sugarbaker's technique]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours - Addendum to commission H21-13]
2009	Committee for New Health Technology Assessment (CNHTA)	[Implantation technology of autologous chondrocyte using fibrin]
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Implantation of a permanent embolic protection in patients with non-valvular attrial fibrillation in left auricular appendage]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Implantation of a lumbar artificial endoprosthesis (anuloplasty/anular repair device)]
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Implantable ventricular assist devices: assessment of evidence and required elements to establish a clinical registry in Québec]
2022	Canary Health Service	[Implantable neurostimulation device for the treatment of drug-resistant pediatric epilepsy]
2008	Committee for New Health Technology Assessment (CNHTA)	[Implantable drug infusion pump implantation]
2024	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Implantable devices for left atrial appendage closure. Monitoring study]
1999	Andalusian Health Technology Assessment Area (AETSA)	[Implantable defibrillators: criteria for clinical indications and decision making on coverage - non-systematic review]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Implantable cardiac monitors in syncope of unknown etiology]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Implantable cardiac defibrillator for primary prevention of sudden death]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Implantable automatic defibrillator for primary prevention of sudden cardiac death in Spain: efficacy, safety, and efficiency]
2013	Institute for Clinical Effectiveness and Health Policy (IECS)	[Implantable and programmable sacral neuromodulator (Interstim®) treatment of urinary, fecal and combined incontinence]
2009	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Implant-supported supraconstructions for the treatment of shortened dental arches]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Impella Recover® 2.5 ventricular assist device]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Impact of the implementation of EFQM in Osakidetza]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation]
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Impact of HTA-research in Austria for the health care system. Part 1: Overview - Update]
2010	Canary Health Service	[Impact of economic evaluation of health technologies on health decisions: a survey of decision-makers]
2012	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of day care centres in monitoring patients with Obstructive Sleep Apnea Syndrome (OSAS)]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of clinical and health services research in advancing knowledge. Applied study to the CAHTA research calls]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of clinical and health services research in advancing knowledge. Applied study to the CAHTA research calls (second edition)]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of clinical and health services research calls on informing decision-making and capacity building. The viewpoint of the researchers]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Impact of a prioritization system for patients on waiting list for hip and knee arthroplasties and cataract surgery]
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Impact evaluation of optimal use guidelines implementation for self-monitoring of blood glucose by adult patients with type 2 diabetes and not using insulin]
2018	Basque Office for Health Technology Assessment (OSTEBA)	[Immunological faecal occult blood test for patients with symptoms compatible with colorectal cancer: recommendation of Clinical Practice Guides and use in the National Health System]
2009	The Regional Health Technology Assessment Centre (HTA-centrum)	[Immunoglobulin in patients with post-polio syndrome]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunoglobulin in chronic inflammatory demyelinating polyneuropathy and other neurological conditions]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunoglobulin for myasthenia gravis chronic treatment]
2010	Andalusian Health Technology Assessment Area (AETSA)	[Immunogenicity and safety of prepandemic vaccines against H5N1 avian flu]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunocyanin in urothelial bladder cancer
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Immunochemical fecal occult blood. Determination of a positivity threshold for the upcoming demonstration projects under Québec's colorectal cancer screening program]
2010	Andalusian Health Technology Assessment Area (AETSA)	[Immunisation against angiotensin II. A therapeutic vaccine against arterial hypertension]
2005	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Immediate breast reconstruction. Systematic review and evaluation of results in a RMI unit in the Community of Madrid]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Imlifidase (kidney transplantation) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Imipenem/cilastatin/relebactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2005	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	[Imatinib in the treatment of chronic myelogenous leukemia]
2005	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	[Imatinib for gastro-intestinal stromal tumors]
2013	The Regional Health Technology Assessment Centre (HTA-centrum)	[Image-guided system for endoscopic sinus surgery]
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Image-guided spinal fusion technology]
2012	Institute for Clinical Effectiveness and Health Policy (IECS)	[Image-guided radiosurgery and radiotherapy for central nervous systems tumors]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Image-guided radiation therapy in liver and lung tumors]
2009	Committee for New Health Technology Assessment (CNHTA)	[IL2RG gene mutation analysis]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Idursulfase (Elaprase) in the treatment of mucopolisacaridosis II
2008	Committee for New Health Technology Assessment (CNHTA)	[IDUA gene, mutation[sequencing]]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idiopathic scoliosis: is video rasterstereography an adequate replacement for radiography in aftercare?]
2006	The Netherlands Organisation for Health Research and Development (ZonMw)	[Identifying optimal diagnostic strategies algorithms with multiple tests. Ancillary study of Optimisation of diagnostic imaging use in patients with acute abdominal pain: cost-effectiveness analysis of imaging strategies (OPTIMA study)]
2012	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Identifying opportunities for health care disinvestment]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Identifying ineffective interventions and health technologies: models and their implementation]
2019	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Identification of psychosocial practices and interventions that support the adaptation and rehabilitation of adults with Prader-Willi Syndrome]
2005	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Identification of preventive health care for children and young people]
2021	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Identification of factors influencing the risk of absconding in a user with an intellectual disability, autism spectrum disorder or a mental health disorder]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idelalisib: benefit assessment according to §35a Social Code Book V]
2017	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idelalisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idelalisib (chronic lymphocytic leukaemia) - Addendum to Commission A16-18]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idelalisib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idecabtagene vicleucel (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idebenone: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2012	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Idebenone for the treatment of Friedreich's ataxia]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idebenone (Leber hereditary optic neuropathy) - assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Icosapent ethyl (cardiovascular risk reduction) - Addendum to Commission A21-113]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (previously untreated chronic lymphocytic leukaemia) – Addendum to Commission A23-04]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (new therapeutic indication, Waldenstroem macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (chronic lymphocytic leukaemia): benefit assessment according to §35a Social Code Book V]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (chronic lymphocytic leukaemia): Addendum to Commission A16-39]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (chronic lymphocytic leukaemia, first line) - Benefit assessment according to §35a Social Code Book V]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib - Benefit assessment according to §35a Social Code Book V]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib - addendum to commission A16-04]